Identification and development of specific inhibitors for insulin-regulated aminopeptidase as a new class of cognitive enhancers

British Journal of Pharmacology

Volumn 164, Issue 1, 2011, Pages 37-47

  Albiston, Anthony L ^a   Diwakarla, Shanti ^a   Fernando, Ruani N ^a   Mountford, Simon J ^b   Yeatman, Holly R ^a   Morgan, Broden ^a   Pham, Vi ^a,e   Holien, Jessica K ^c   Parker, Michael W ^c,d   Thompson, Philip E ^b   Chai, Siew Yeen ^a,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

angiotensin IV; drug development; glucose; GLUT4; memory; oxytocinase; peptidomimetic; vasopressin

Indexed keywords

AMINOPEPTIDASE; ANGIOTENSIN II [3-8]; BENZOPYRAN DERIVATIVE; CHOLECYSTOKININ OCTAPEPTIDE; DONEPEZIL; ENKEPHALIN; ENZYME INHIBITOR; ETHYL 2 ACETYLAMINO 7 HYDROXY 4 PYRIDIN 3 YL 4H CHROMENE 3 CARBOXYLATE; ETHYL 2 ACETYLAMINO 7 HYDROXY 4 QUINOLIN 3 YL 4H CHROMENE 3 CARBOXYLATE; GLUCOSE TRANSPORTER 4; HFI 419; HFI 435; HFI 437; INHIBITORS OF INSULIN REGULATED AMINOPEPTIDASE; INHIBITORS OF INSULIN REGULATED AMINOPEPTIDASE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMANTINE; MEMBRANE PROTEIN; NOOTROPIC AGENT; OXYTOCIN; PEPTIDE HORMONE; PEPTIDOMIMETIC AGENT; SOMATOSTATIN; UNCLASSIFIED DRUG; VASOPRESSIN;

ALZHEIMER DISEASE; CARBOXY TERMINAL SEQUENCE; CATALYSIS; COGNITIVE DEFECT; DEMENTIA; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FACILITATION; GLUCOSE TRANSPORT; HUMAN; KNOCKOUT MOUSE; MEMORY CONSOLIDATION; MEMORY DISORDER; MENTAL PERFORMANCE; MENTAL TASK; MOLECULAR DOCKING; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; SEIZURE;

ANIMALS; COGNITION; CYSTINYL AMINOPEPTIDASE; ENZYME INHIBITORS; HUMANS; NOOTROPIC AGENTS;

EID: 79961241498     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01402.x     Document Type: Review

References (81)

1. Addlagatta A, Gay L, Matthews BW, (2006). Structure of aminopeptidase N from Escherichia coli suggests a compartmentalized, gated active site. Proc Natl Acad Sci U S A 103: 13339-13344. (Pubitemid 44380109)
2. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, et al,. (2001). Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin regulated aminopeptidase. J Biol Chem 276: 48263-48266.
3. Albiston AL, Pederson ES, Burns P, Purcell B, Wright JW, Harding JW, et al,. (2004). Reversal of scopolamine-induced memory deficits by LVV-hemorphin 7 in rats in the passive avoidance and Morris water maze paradigms. Behav Brain Res 154: 239-243. (Pubitemid 39070471)
4. Albiston AL, Peck GR, Yeatman HR, Fernando R, Ye S, Chai SY, (2007). Therapeutic targeting of insulin-regulated aminopeptidase: heads and tails? Pharmacol Ther 116: 417-427. (Pubitemid 350116937)
5. Albiston AL, Morton CJ, Ng HL, Pham V, Yeatman HR, Ye S, et al,. (2008). Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase. Faseb J 22: 4209-4217.
6. Albiston AL, Fernando RN, Yeatman HR, Burns P, Ng L, Daswani D, et al,. (2010a). Gene knockout of insulin-regulated aminopeptidase: loss of the specific binding site for angiotensin IV and age-related deficit in spatial memory. Neurobiol Learn Mem 93: 19-30.
7. Albiston AL, Pham V, Ye S, Ng L, Lew RA, Thompson PE, et al,. (2010b). Phenylalanine-544 plays a key role in substrate and inhibitor binding by providing a hydrophobic packing point at the active site of insulin-regulated aminopeptidase. Mol Pharmacol 78: 600-607.
8. Andersson H, Demaegdt H, Vauquelin G, Lindeberg G, Karlén A, Hallberg M, (2008). Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2. Bioorg Med Chem 16: 6924-6935.
9. Andersson H, Demaegdt H, Vauquelin G, Lindeberg G, Karlen A, Hallberg M, et al,. (2010). Disulfide cyclized tripeptide analogues of angiotensin IV as potent and selective inhibitors of insulin-regulated aminopeptidase (IRAP). J Med Chem 53: 8059-8071.
10. Axén A, Lindeberg G, Demaegdt H, Vauquelin G, Karlen A, Hallberg M, (2006). Cyclic insulin-regulated aminopeptidase (IRAP)/AT4 receptor ligands. J Pept Sci 12: 705-713. (Pubitemid 44697843)
11. Axén A, Andersson H, Lindeberg G, Rönnholm H, Kortesmaa J, Demaegdt H, et al,. (2007). Small potent ligands to the insulin-regulated aminopeptidase (IRAP)/AT(4) receptor. J Pept Sci 13: 434-444. (Pubitemid 47082893)
12. Barco A, Patterson S, Alarcon JM, Gromova P, Mata-Roig M, Morozov A, et al,. (2005). Gene expression profiling of facilitated L-LTP in VP16-CREB mice reveals that BDNF is critical for the maintenance of LTP and its synaptic capture. Neuron 48: 123-137. (Pubitemid 41384170)
13. Berankova Z, Sorm F, (1961). Characterization of purified preparations of serum oxytocinase. Coll Czech Chem Commun 26: 2557-2561.
14. Beyer CE, Dwyer JM, Platt BJ, Neal S, Luo B, Ling HP, et al,. (2010). Angiotensin IV elevates oxytocin levels in the rat amygdala and produces anxiolytic-like activity through subsequent oxytocin receptor activation. Psychopharmacology (Berl) 209: 303-311.
15. Boulanger LM, (2009). Immune proteins in brain development and synaptic plasticity. Neuron 64: 93-109.
16. Braszko JJ, (2004). Involvement of D1 dopamine receptors in the cognitive effects of angiotensin IV and des-Phe6 angiotensin IV. Peptides 25: 1195-1203. (Pubitemid 38885734)
17. Braszko JJ, (2009). Dopamine D4 receptor antagonist L745,870 abolishes cognitive effects of intracerebroventricular angiotensin IV and des-Phe(6)-Ang IV in rats. Eur Neuropsychopharmacol 19: 85-91.
18. Braszko JJ, (2010). Participation of D 1-4 dopamine receptors in the pro-cognitive effects of angiotensin IV and des-Phe 6 angiotensin IV. Neurosci Biobehav Rev 34: 343-350.
19. Braszko JJ, Kupryszewski G, Witczuk B, Wisniewski K, (1988). Angiotensin II-(3-8)-hexapeptide affects motor activity, performance of passive avoidance and a conditioned avoidance response in rats. Neuroscience 27: 777-783. (Pubitemid 19025386)
20. Braszko JJ, Wielgat P, Walesiuk A, (2008). Effect of D(3) dopamine receptors blockade on the cognitive effects of angiotensin IV in rats. Neuropeptides 42: 301-309.
21. Bryant NJ, Govers R, James DE, (2002). Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol 3: 267-277. (Pubitemid 34619262)
22. Buccafusco JJ, (2009). Emerging cognitive enhancing drugs. Expert Opin Emerg Drugs 14: 577-589.
23. de Bundel D, Smolders I, Yang R, Albiston AL, Michotte Y, Chai SY, (2009). Angiotensin IV and LVV-Haemorphin 7 enhance spatial working memory in rats: effects on hippocampal glucose levels and blood flow. Neurobiol Learn Mem 92: 19-26.
24. Chai SY, Lee JH, Matscos D, McDowall SG, Mendelsohn FAO, Robel P, et al,. (2001). Angiotensin AT4 receptor distribution in mouse brain and its possible role in facilitation of spatial memory. J Neurochem 78 (Suppl. 1): 15.
25. Cheng DY, DeWitt BJ, Dent EL, Nossaman BD, Kadowitz PJ, (1994). Analysis of responses to angiotensin IV in the pulmonary vascular bed of the cat. Eur J Pharmacol 261: 223-227. (Pubitemid 24263226)
26. Corriveau RA, Huh GS, Shatz CJ, (1998). Regulation of class I MHC gene expression in the developing and mature CNS by neural activity. Neuron 21: 505-520. (Pubitemid 28475503)
27. Dash PK, Orsi SA, Moore AN, (2006). Spatial memory formation and memory-enhancing effect of glucose involves activation of the tuberous sclerosis complex-Mammalian target of rapamycin pathway. J Neurosci 26: 8048-8056. (Pubitemid 44315129)
28. Einstein EB, Patterson CA, Hon BJ, Regan KA, Reddi J, Melnikoff DE, et al,. (2010). Somatostatin signaling in neuronal cilia is critical for object recognition memory. J Neurosci 30: 4306-4314.
29. Fernando R, Larm J, Albiston AL, Chai SY, (2005). Distribution and cellular localization of the insulin regulated aminopeptidase (IRAP) in the rat central nervous system. J Comp Neurol 487: 372-390. (Pubitemid 40756877)
30. Fernando RN, Luff SE, Albiston AL, Chai SY, (2007). Sub-cellular localization of insulin-regulated membrane aminopeptidase, IRAP, to vesicles in neurons. J Neurochem 102: 967-976. (Pubitemid 47057310)
31. Fernando RN, Albiston AL, Chai SY, (2008). The insulin-regulated aminopeptidase IRAP is colocalised with GLUT4 in the mouse hippocampus-potential role in modulation of glucose uptake in neurones? Eur J Neurosci 28: 588-598. (Pubitemid 352040410)
32. Georgiadou D, Hearn A, Evnouchidou I, Chroni A, Leondiadis L, York IA, et al,. (2010). Placental leucine aminopeptidase efficiently generates mature antigenic peptides in vitro but in patterns distinct from endoplasmic reticulum aminopeptidase 1. J Immunol 185: 1584-1592.
33. Golding BJ, Overall AD, Brown G, Gard PR, (2010). Strain differences in the effects of angiotensin IV on mouse cognition. Eur J Pharmacol 641: 154-159.
34. Herbst JJ, Ross SA, Scott HM, Bobin SA, Morris NJ, Lienhard GE, et al,. (1997). Insulin stimulates cell surface aminopeptidase activity toward vasopressin in adipocytes. Am J Physiol 272 (4 Pt 1): E600-E606.
35. Huh GS, Boulanger LM, Du H, Riquelme PA, Brotz TM, Shatz CJ, (2000). Functional requirement for class I MHC in CNS development and plasticity. Science 290: 2155-2159. (Pubitemid 32001597)
36. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H, van den Bussche H, (2005). Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. Br Med J 331: 321-327.
37. Keller SR, Scott HM, Mastick CC, Aebersold R, Lienhard GE, (1995). Cloning and characterization of a novel insulin-regulated membrane aminopeptidase from Glut4 vesicles. J Biol Chem 270: 23612-23618.
38. Keller SR, Davis AC, Clairmont KB, (2002). Mice deficient in the insulin-regulated membrane aminopeptidase show substantial decreases in glucose transporter GLUT4 levels but maintain normal glucose homeostasis. J Biol Chem 277: 17677-17686. (Pubitemid 34967572)
39. Kobori T, Goda K, Sugimoto K, Ota T, Tomisawa K, (2000). Amino compounds and angiotensin IV receptor agonists. US Patent 5439919. Taisho Pharmaceutical Co., Ltd.
40. Korol DL, Gold PE, (1998). Glucose, memory, and aging. Am J Clin Nutr 67: 764S-771S. (Pubitemid 28153181)
41. Kramar EA, Armstrong DL, Ikeda S, Wayner MJ, Harding JW, Wright JW, (2001). The effects of angiotensin IV analogs on long-term potentiation within the CA1 region of the hippocampus in vitro. Brain Res 897: 114-121. (Pubitemid 32244358)
42. Lee MK, Graham SN, Gold PE, (1988). Memory-enhancement with post-training intraventricular glucose injections in rats. Behav Neurosci 102: 591-595.
43. Lee J, Albiston AL, Allen AM, Mendelsohn FAO, Ping SE, Barrett GL, et al,. (2004). Effect of intracerebroventricular injection of AT4 receptor ligands, Nle1-angiotensin IV and LVv-hemorphin 7, on spatial learning in rats. Neuroscience 124: 341-349. (Pubitemid 38229654)
44. Lew RA, Mustafa T, Ye S, McDowall SG, Chai SY, Albiston AL, (2003). Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP). J Neurochem 86: 344-350. (Pubitemid 36842433)
45. Loufrani L, Henrion D, Chansel D, Ardaillou R, Levy BI, (1999). Functional evidence for an angiotensin IV receptor in rat resistance arteries. J Pharmacol Exp Ther 291: 583-588. (Pubitemid 29503528)
46. Lukaszuk A, Demaegdt H, Szemenyei E, Tóth G, Tymecka D, Misicka A, et al,. (2008). Beta-homo-amino acid scan of angiotensin IV. J Med Chem 51: 2291-2296.
47. Lukaszuk A, Demaegdt H, Feytens D, Vanderheyden P, Vauquelin G, Tourwé D, (2009). The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues. J Med Chem 52: 5612-5618.
48. McEwen BB, (2004). De Wied and colleagues IV: research into mechanisms of action by which vasopressin and oxytocin influence memory processing. Adv Pharmacol 50: 177-225. (Pubitemid 39753164)
49. McGowan S, Porter CJ, Lowther J, Stack CM, Golding SJ, Skinner-Adams TS, et al,. (2009). Structural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidase. Proc Natl Acad Sci U S A 106: 2537-2542.
50. McNay EC, Fries TM, Gold PE, (2000). Decreases in rat extracellular hippocampal glucose concentration associated with cognitive demand during a spatial task. Proc Natl Acad Sci U S A 97: 2881-2885. (Pubitemid 30159266)
51. Matsumoto H, Hattori A, Mizutani S, Tsujimoto M, (2001a). Cleavage of peptide hormones by placental leucine aminopeptidase/oxytocinase. In:, Mizutani, et al. (eds). Cell-Surface Aminopeptidases: Basic and Clinical Aspects. Elsevier Science BV: Nagoya, pp. 295-299.
52. Matsumoto H, Nagasaka T, Hattori A, Rogi T, Tsuruoka N, Mizutani S, et al,. (2001b). Expression of placental leucine aminopeptidase/oxytocinase in neuronal cells and its action on neuronal peptides. Eur J Biochem 268: 3259-3266. (Pubitemid 32823000)
53. Moeller I, Lew RA, Mendelsohn FA, Smith AI, Brennan ME, Tetaz TJ, et al,. (1997). The globin fragment LVV-hemorphin-7 is an endogenous ligand for the AT4 receptor in the brain. J Neurochem 68: 2530-2537. (Pubitemid 27218176)
54. 1-Angiotensin IV mitigates scopolamine-induced spatial working memory deficits. Peptides 31: 2209-2215.
55. Olson ML, Olson EA, Qualls JH, Stratton JJ, Harding JW, Wright JW, (2004). Norleucine1-angiotensin IV alleviates mecamylamine-induced spatial memory deficits. Peptides 25: 233-241. (Pubitemid 38520053)
56. Parent MB, Leaurey PT, Wilkniss S, Gold PE, (1997). Intraseptal infusions of muscimol impair spontaneous alternation performance: infusions of glucose into the hippocampus, but not the medial septum, reverse the deficit. Neurobiol Learn Mem 68: 75-85. (Pubitemid 27423893)
57. Parkes M, White KG, (2000). Glucose attenuation of memory impairments. Behav Neurosci 114: 307-319. (Pubitemid 30488991)
58. Pederson ES, Harding JW, Wright JW, (1998). Attenuation of scopolamine-induced spatial learning impairments by an angiotensin IV analog. Regul Pept 74: 97-103. (Pubitemid 28288970)
59. Pederson ES, Krishnan R, Harding JW, Wright JW, (2001). A role for the angiotensin AT4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. Regul Pept 102: 147-156. (Pubitemid 33135576)
60. Pham V, Burns P, Albiston AL, Yeatman HR, Ng L, Diwakarla S, et al,. (2009). Reproduction and maternal behaviour in insulin regulated aminopeptidase (IRAP) knockout mice. Peptides 30: 1861-1865.
61. Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili F, Scheltens P, et al,. (2006). Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry 77: 714-718. (Pubitemid 43837193)
62. Ragozzino ME, Pal SN, Unick K, Stefani MR, Gold PE, (1998). Modulation of hippocampal acetylcholine release and spontaneous alternation scores by intrahippocampal glucose injections. J Neurosci 18: 1595-1601. (Pubitemid 28082440)
63. Rimmele U, Hediger K, Heinrichs M, Klaver P, (2009). Oxytocin makes a face in memory familiar. J Neurosci 29: 38-42.
64. Rogi T, Tsujimoto M, Nakazato H, Mizutani S, Tomoda Y, (1996). Human placental leucine aminopeptidase/oxytocinase. A new member of type II membrane-spanning zinc metallopeptidase family. J Biol Chem 271: 56-61.
65. Rosenbloom AA, Sack J, Fisher DA, (1975). The circulating vasopressinase of pregnancy: species comparison with radioimmunoassay. Am J Obstet Gynecol 121: 316-320.
66. Saveanu L, Carroll O, Lindo V, Del Val M, Lopez D, Lepelletier Y, et al,. (2005). Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat Immunol 6: 689-697. (Pubitemid 41716742)
67. Saveanu L, Carroll O, Weimershaus M, Guermonprez P, Firat E, Lindo V, et al,. (2009). IRAP identifies an endosomal compartment required for MHC class I cross-presentation. Science 325: 213-217.
68. Segura E, Albiston AL, Wicks IP, Chai SY, Villadangos JA, (2009). Different cross-presentation pathways in steady-state and inflammatory dendritic cells. Proc Natl Acad Sci U S A 106: 20377-20381.
69. Stragier B, Clinckers R, Meurs A, De Bundel D, Sarre S, Ebinger G, et al,. (2006). Involvement of the somatostatin-2 receptor in the anti-convulsant effect of angiotensin IV against pilocarpine-induced limbic seizures in rats. J Neurochem 98: 1100-1113. (Pubitemid 44127786)
70. Thomas SJ, Grossberg GT, (2009). Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging 4: 367-377.
71. Thunnissen MM, Nordlund P, Haeggstrom JZ, (2001). Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation. Nat Struct Biol 8: 131-135. (Pubitemid 32117699)
72. Wallis MG, Lankford MF, Keller SR, (2007). Vasopressin is a physiological substrate for the insulin-regulated aminopeptidase IRAP. Am J Physiol Endocrinol Metab 293: E1092-E1102. (Pubitemid 47535842)
73. Waters SB, D'Auria M, Martin SS, Nguyen C, Kozma LM, Luskey KL, (1997). The amino terminus of insulin-responsive aminopeptidase causes Glut4 translocation in 3T3-L1 adipocytes. J Biol Chem 272: 23323-23327. (Pubitemid 27392470)
74. Wayner MJ, Armstrong DL, Phelix CF, Wright JW, Harding JW, (2001). Angiotensin IV enhances LTP in rat dentate gyrus in vivo. Peptides 22: 1403-1414. (Pubitemid 32770010)
75. Wisniewski K, Borawska M, Car H, (1993). The effect of angiotensin II and its fragments on post-alcohol impairment of learning and memory. Pol J Pharmacol 45: 23-29. (Pubitemid 23278652)
76. Wright JW, Miller-Wing AV, Shaffer MJ, Higginson C, Wright DE, Hanesworth JM, et al,. (1993). Angiotensin II(3-8) (ANG IV) hippocampal binding: potential role in the facilitation of memory. Brain Res Bull 32: 497-502. (Pubitemid 23251954)
77. Wright JW, Clemens JA, Panetta JA, Smalstig EB, Weatherly LA, Kramar EA, et al,. (1996). Effects of LY231617 and angiotensin IV on ischemia-induced deficits in circular water maze and passive avoidance performance in rats. Brain Res 717: 1-11. (Pubitemid 26155069)
78. Wright JW, Stubley L, Pederson ES, Kramar EA, Hanesworth JM, Harding JW, (1999). Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J Neurosci 19: 3952-3961. (Pubitemid 29222269)
79. Wright JW, Kramár EA, Myers ED, Davis CJ, Harding JW, (2003). Ethanol-induced suppression of LTP can be attenuated with an angiotensin IV analog. Regul Pept 113: 49-56. (Pubitemid 36398441)
80. Yamahara N, Nomura S, Suzuki T, Itakura A, Ito M, Okamoto T, et al,. (2000). Placental leucine aminopeptidase/oxytocinase in maternal serum and placenta during normal pregnancy. Life Sci 66: 1401-1410. (Pubitemid 30152311)
81. Yamamoto BJ, Elias PD, Masino JA, Hudson BD, McCoy AT, Anderson ZJ, et al,. (2010). The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor. J Pharmacol Exp Ther 333: 161-173.